2. Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

3. Diabetes in Cardiology Cohorts

4. High Residual Risk of Diabetes: Observations from the Statin Trials

5. Mortality Impact of Glycemic Control: UGDP

6. Blood Glucose and Vascular Risk in Diabetes: UKPDS Findings

7. UKPDS Metformin Sub-Study: CHD Events

8. Off Target Adverse Drug Effects

9. ADOPT: Cardiovascular events

10. Summary of RCT & Meta-Analysis Data on TZDs and MI Risk

11. CV Effects of More Intensive Glucose Control in Recent Large-Scale Trials

12. 2009 ADA/AHA/ACC Statement Recommendations

13. Cautions for Diabetes Medications in CHD Patients: Beware the Product Label

14. Proposed Algorithm for Glucose Treatment in T2DM Patients With/At risk for CVD

15. Proposed Algorithm for Glucose Treatment in T2DM Patients With/At risk for CVD

16. 2012 Guidance from ADA/EASD for Glucose Management

17. ORIGIN Key Results

18. Converging Pressures for Regulatory Change: Beyond A1C

19. Summary of Revised Guidance for Diabetes Drug Development

20. New FDA Regulatory Guidance for Drugs for Type 2 Diabetes

21. Present Landscape of CVD Outcomes Trials in Type 2 DM

22. SAVOR-TIMI 53 Summary

23. SAVOR-TIMI 53 Summary

24. EXAMINE

25. EXAMINE

26. Conclusions

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)

30. Abbreviations (cont)

31. References

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)